American Type Culture Collection

American Type Culture Collection (operating as Atcc), a nonprofit biological resource center headquartered in Manassas, Virginia, provides collection, authentication, production, preservation, and distribution of microorganisms, cell lines, reagents, and biological reference materials to federal health, defense, and research agencies as a prime contractor (99% of recent awards). The organization competes full-and-open on all awards; no set-asides appear in the source data.

Atcc's customer base is heavily concentrated in HHS health agencies. The top five funding agencies account for 31% of combined potential value across all awards, led by the Department of Health and Human Services National Institute of Allergy and Infectious Diseases (39 awards, $1.88 billion combined potential value), followed by CDC Pittsburgh (31 awards, $964.6 million), the National Cancer Institute (32 awards, $443.3 million), the Office of the Assistant Secretary for Preparedness and Response (12 awards, $346.6 million), and CDC's Office of Acquisition Services (10 awards, $196.4 million). This concentration reflects Atcc's core mission of supporting infectious disease research, medical countermeasure development, and pandemic preparedness across civilian health agencies; defense work is routed through specific initiatives such as the Joint PEO Chemical and Biological Defense RAPID (Rapid Access to Products in Development) program and the Defense Health Agency.

Atcc holds a substantial portfolio of indefinite delivery vehicles spanning research, manufacturing, and distribution. The organization operates a $334.3 million single-award contract with NIAID for operation of the Biological and Emerging Infections Research Resources Program (BEI-RRP) central repository, which collects, authenticates, produces, preserves, and distributes microorganisms and reagents to approximately 12,000 registered users maintaining around 17,000 unique items. A $146.3 million single-award NIAID contract for preclinical models of infectious diseases supports animal and alternative models for infectious disease research and medical countermeasure evaluation. The organization also holds a $136.6 million single-award NIAID contract for evaluation and testing services for vaccines and biologics, a $48 million multiple-award NIAID contract for vaccine manufacturing services for infectious diseases with cGMP compliance, a $148 million multiple-award CDC contract for diagnostic testing development and manufacturing capacity during public health emergencies, a $320 million single-award National Cancer Institute contract for field and biospecimen support services, a $30 million single-award NIAID contract for preclinical services supporting biopharmaceutical product development, and a $4.06 million single-award National Cancer Institute contract for retrovirus assay and viral stock preparation. Atcc also holds a position on the OASIS+ Unrestricted government-wide acquisition contract (GSA) and operates under an Other Transaction IDV with the Joint PEO Chemical and Biological Defense for storage and stability testing of medical countermeasures under the RAPID program. Recent task-order activity includes a $15.5 million NIAID delivery order (February 2024) for production of well-characterized challenge material of Biosafety Level 3 and 4 viruses under the In Vitro Assessments of Antimicrobial Activity (IVAAA) IDIQ, a $7.3 million CDC definitive contract (May 2026) for influenza serology testing, a $4.3 million NIAID delivery order (July 2026) for screening countermeasures for seasonal and high pathogen avian influenza in human lung microphysiological systems, and a $2.4 million NIAID delivery order (July 2026) for screening countermeasures for viral encephalitis in human central nervous system and blood brain barrier models.

Recent award activity has remained stable, averaging 9 to 17 awards per year over the past five years, with 12 awards in 2026 to date. Nine awards with a combined potential value of $106.4 million face ultimate completion within the next twenty-four months and therefore represent recompete exposure. The organization's top parent vehicle by task-order volume is Indefinite Delivery Contract 75A50120D00013 (9 task orders, $96.4 million combined potential value), followed by the In Vitro Assessments of Antimicrobial Activity IDIQ (8 task orders, $19.1 million).

Atcc operates predominantly as a prime (99% of awards) and builds significant portions of its federal delivery capacity internally. Across SCI-reportable prime service contracts, the organization deployed roughly 72.9 FTEs in FY2022, peaked at 140 FTEs in FY2024, and operated at 128 FTEs in FY2025. SCI-reported invoiced revenue across prime contracts totaled $197.4 million over FY2022–FY2025 ($26.2 million in FY2022, $55 million in FY2023, $57.8 million in FY2024, and $58.5 million in FY2025). Government-paid hourly rates on federal services contracts captured in SCI ranged from a 10th percentile of $104.37/hr to a median of $210.32/hr to a 90th percentile of $386.08/hr, reflecting the mix of specialized scientific and technical labor. Across SCI-reportable prime contracts, named subcontractors performed approximately 9% of total contractor hours, with 27 distinct subcontractors engaged; key subcontractors have included Colorado State University's Veterinary Diagnostic Laboratory, the University of Texas Medical Branch at Galveston, the CDC Foundation, and Xpand Corporation. In its limited subcontractor role, Atcc performs sample aliquoting and repository management services to primes including Government Scientific Source Inc., Agilent Technologies, and IT1 Source LLC on NCI operational and SeroNet tasks.

The organization also operates as a federal grant recipient with NIAID as the primary grantor. Grant work has centered on facility expansion and biodefense infrastructure: a project grant awarded September 6, 2023, supports construction and commissioning of a biomaterial manufacturing suite within a planned high-containment facility to provide large-scale production of well-characterized challenge materials for priority pathogens, with completion targeted for November 30, 2026; a second project grant awarded September 16, 2022, supports renovations to Atcc's existing 7,500-square-foot high-containment facility to support pandemic preparedness and infectious disease research, with completion targeted for May 31, 2026. Atcc also acts as a sub-recipient to academic institutions on NIAID-funded research projects, including subawards to Yale University for parasite immunology studies, Albert Einstein College of Medicine for Mycobacterium tuberculosis genetic studies, the University of Cincinnati for Pneumocystis cultivation research, Harvard College for organism cultivation work, and Iowa State University for artificial intelligence and microbiome studies.